![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ONCOFID®-P is an anticancer drug in advanced clinical development for the loco-regional treatment of non-muscle invasive bladder cancer, on which it has already demonstrated potent efficacy and excellent tolerability.
Lead Product(s): Paclitaxel
Therapeutic Area: Oncology Product Name: Oncofid-P
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2021
Details:
The agreement covers the registrations, trademarks, and related commercial rights of seven products, including four corticosteroids and one non-steroidal anti-inflammatory drug, across Europe and Emerging Markets.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment March 23, 2021